Phase 1 open-label RCT in 242 adults: mRNA virus-like particle vaccines AZD9838 and AZD6563 were well tolerated, with fewer solicited reactions than 30 μg BNT162b2; 10 μg AZD6563 gave neutralising antibody levels similar to BNT162b2.
RCTn = 242
Oyedele et al. A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial